Antares Pharma

Antares Pharma is a revenue-generating product-focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved products. Its products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. It focuses on self-injection pharmaceutical products and technologies and topical gel-based products. Its subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto-injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for Antares' corporate Human Resources (“HR”) strategy and development.

Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources

EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.

Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

HALIFAX, Nova Scotia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann to the board effective immediately.

MedMira strengthen its Board with New Appointment

EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the divestiture of OTREXUP® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP® WIP and finished inventory. Under the terms of the asset purchase agreement, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totalling $26.0 million in 2022.

Antares Pharma Announces Divestiture of Otrexup®

EWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021.

Antares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Apple

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and -0.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Q3 Earnings Match Estimates

Increased Revenue 20% Year-Over-Year to $48.2 Million

Antares Pharma Reports Third Quarter 2021 Financial and Operating Results

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma (ATRS) Reports Next Week: What to Expect

EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED®, a subcutaneous testosterone enanthate injection, was accepted as on oral presentation at the 22nd Annual Fall Scientific Meeting of SMSNA in Scottsdale, AZ on October 21-24, 2021.

Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA

EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens.

Antares Pharma to Report Third Quarter 2021 Financial and Operating Results

Pharmacokinetic data results expected in 1Q 2022 Pharmacokinetic data results expected in 1Q 2022

Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held on September 13-15, 2021.

Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Meridian Bioscience

These healthcare stocks have their warts, but the price is right for long-term investors.

Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying

Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript

Increased Revenue 39% Year-Over-Year to $45.0 Million

Antares Pharma Reports Second Quarter 2021 Financial and Operating Results

Antares Pharma (ATRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma (ATRS) Earnings Expected to Grow: Should You Buy?

EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens.

Antares Pharma to Report Second Quarter 2021 Financial and Operating Results

The FDA has accepted Antares Pharma Inc's (NASDAQ: ATRS) Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue.  The active IND enables Antares to initiate a Phase 1 study for ATRS-1902 for acute adrenal insufficiency, known as an adrenal crisis, in adults and adolescents.

Antares To Start Testing ATRS-1902 With Injector Technology In Patients With Adrenal Crisis

EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue. The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.

Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue

GT Biopharma Inc

ObsEva

Ocugen, Inc.

Odonate Therapeutics

Palatin Technologies

Seelos Therapeutics

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

7 Penny Stocks For Your Watch List This Week If You Like Biotech In July

Ad hoc announcement pursuant to Art. 53 LR

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

EWING, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical study of ATRS-1902 for adrenal crisis rescue. The IND application for ATRS-1902, and its corresponding development program, supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.

Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis Rescue

EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.

Antares Pharma to Present at the Raymond James Human Health Innovations Conference

EWING, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference.

News for Antares Pharma Stock (ATRS)